Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
Heres what $1k invested in Mesoblast shares a month ago is worth now
Share Gainers
After 50% or more share price growth, should you sell these ASX 200 winners?
Share Gainers
These were the best performing ASX 200 shares in July
Broker Notes
4 ASX shares to buy this week: experts
Broker Notes
Leading brokers name 3 ASX shares to buy today
Healthcare Shares
Why Mesoblast shares can keep storming higher
Share Gainers
Here are the top 10 ASX 200 shares today
Share Gainers
Why BHP, Catalyst Metals, Mesoblast, and Pilbara Minerals shares are shooting higher
Healthcare Shares
The Mesoblast share price just rocketed 38%! Here's why
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
These 5 ASX 200 healthcare shares gained the most weight in FY25
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
